Eton Pharmaceuticals Posts 73% Q1 Sales Growth, Raises Guidance Above $120M
Eton Pharmaceuticals delivered 73% year-over-year product revenue growth in Q1 and raised full-year revenue guidance to over $120 million from $110 million while maintaining a 24% adjusted EBITDA margin and targeting over 30% for the year. The company also reported Q1 EPS of $0.05 versus a $0.10 consensus.
1. Record Q1 Sales Growth and Guidance Increase
Q1 record product sales up 73% year-over-year drove Eton to raise full-year revenue guidance to over $120 million (from $110 million), reflecting strong portfolio performance led by established therapies and newly launched treatments.
2. New Product Launches and Early Execution Issues
The launches of Desmoda and Hemangio are expected to underpin future growth; however, Hemangio’s mid-quarter rollout, patient transfer complexities, and high assistance-program volume could limit near-term revenue contributions by 60–65%.
3. Profitability Outlook and Margin Expansion
Eton delivered a 24% adjusted EBITDA margin in Q1 and projects exceeding 30% for the full year, despite a 14% rise in general and administrative expenses due to higher FDA fees and loss of orphan-PDUFA exemption.
4. Q1 Earnings Miss and Market Reaction
The company reported Q1 EPS of $0.05 versus a $0.10 consensus estimate and $0.07 a year ago, reflecting upfront launch costs and ramp expenses, which may temper near-term share performance.